CN
BACK to A-Z
XIA Xuejun Principal Investigator
Professor

Department :

Department of Pharmaceutics

Platform :

Beijing Key Laboratory of Drug Delivery Technology and Novel Formulation
Chinese Academy of Medical Sciences Key Laboratory of Anti-DR TB Innovative Drug Research

Contact Details

Xia Xuejun's group
xjxia@imm.ac.cn
Brief Introduction

Xia Xuejun graduated from the School of Pharmacy, Beijing Medical University in 1994, and joined the Institute of Materia Medica, Chinese Academy of Medical Sciences in the same year. In 2012, she was appointed as a professor. Her research fields include "innovative drug delivery route and dosage form design", "insoluble drug solubilization technology", "nano delivery system", "tumor targeted preparations", "mucosal drug delivery preparations", "oral controlled release preparations" and so on. Xia has conducted and participated in a number of national, provincial and ministerial-level scientific research projects. She also participated in the completion of more than 20 new drug development projects, and obtained 19 new drug certificates and 9 clinical approvals, achieving a good achievement conversion. As a result of these studies, she has published more than 50 papers and obtained more than 40 national or PCT authorized patents. In addition, Xia won the third prize of the 2009 Beijing Municipal Science and Technology Progress Award and the third prize of the 2009 China Medical Science and Technology Award.

Achievements

Papers

1. Factors affecting the buccal delivery of deformable nanovesicles based on insulin–phospholipid complex: an in vivo investigation. Drug Delivery. 2020, 2: 901-908.

2. Stabilization of deformable nanovesicles based on insulin-phospholipid complex by freeze-drying. Pharmaceutics. 2019, 11: 539.

3. Mechanisms of deformable nanovesicles based on insulin-phospholipid complex for enhancing buccal delivery of insulin. International Journal of Nanomedicine. 2018, 13: 7319-7331.

4. Development of a validated LC-APCI-MS/MS method to study the plasma and tumor distribution of CHO-PTX intravenous lipid emulsion. Journal of Pharmaceutical and Biomedical Analysis. 2016, 117: 532-543.

5. Cellular uptake mechanism and comparative evaluation of antineoplastic effects of paclitaxel–cholesterol lipid emulsion on triple-negative and non-triple-negative breast cancer cell lines. International Journal of Nanomedicine. 2016, 11: 4125-4140.

6. Effect of high-pressure homogenization preparation on mean globule size and large-diameter tail of oil-in-water injectable emulsions. Journal of Food and Drug Analysis. 2015, 23: 828-835.

Books

Honors & Awards